76,015 Shares in Quantum-Si Incorporated $QSI Bought by MetLife Investment Management LLC

MetLife Investment Management LLC bought a new position in shares of Quantum-Si Incorporated (NASDAQ:QSI) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 76,015 shares of the company’s stock, valued at approximately $91,000.

Other institutional investors have also recently made changes to their positions in the company. Cetera Investment Advisers purchased a new position in shares of Quantum-Si during the fourth quarter worth $36,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Quantum-Si during the fourth quarter worth $36,000. Balyasny Asset Management L.P. purchased a new position in shares of Quantum-Si during the fourth quarter worth $36,000. Alpine Global Management LLC purchased a new position in shares of Quantum-Si during the fourth quarter worth $37,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Quantum-Si during the fourth quarter worth $51,000. Hedge funds and other institutional investors own 39.90% of the company’s stock.

Analyst Upgrades and Downgrades

QSI has been the subject of several recent research reports. Alliance Global Partners reissued a “buy” rating on shares of Quantum-Si in a report on Friday, May 16th. HC Wainwright reissued a “buy” rating and set a $5.50 target price on shares of Quantum-Si in a report on Monday, May 19th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and issued a $1.00 price objective on shares of Quantum-Si in a report on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Quantum-Si currently has an average rating of “Moderate Buy” and an average target price of $3.48.

Quantum-Si Stock Performance

QSI opened at $1.12 on Thursday. Quantum-Si Incorporated has a fifty-two week low of $0.61 and a fifty-two week high of $5.77. The company has a fifty day moving average of $1.44 and a two-hundred day moving average of $1.45. The stock has a market capitalization of $226.79 million, a price-to-earnings ratio of -1.65 and a beta of 2.85.

Quantum-Si (NASDAQ:QSI) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). Quantum-Si had a negative net margin of 3,120.14% and a negative return on equity of 44.57%. The company had revenue of $0.59 million during the quarter, compared to analysts’ expectations of $1.28 million. On average, equities research analysts forecast that Quantum-Si Incorporated will post -0.65 earnings per share for the current year.

Insider Transactions at Quantum-Si

In other news, CEO Jeffrey Alan Hawkins sold 23,705 shares of the business’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $1.61, for a total transaction of $38,165.05. Following the completion of the sale, the chief executive officer owned 2,623,011 shares of the company’s stock, valued at $4,223,047.71. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John S. Vieceli sold 21,923 shares of the business’s stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $1.61, for a total transaction of $35,296.03. Following the sale, the insider directly owned 842,586 shares of the company’s stock, valued at $1,356,563.46. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,252 shares of company stock valued at $87,346 in the last three months. Corporate insiders own 30.04% of the company’s stock.

Quantum-Si Profile

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.